Reimbursement Scheme Veoza®
Reimbursement Scheme for VEOZA® (fezolinetant) 45 mg for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms…
PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS
General information
The pharmacist has dispensed Adempas® 0.5 or 1mg to the patient. The health insurer will not…
Update Reimbursement Scheme Elvanse®
TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg…
General information
The pharmacist has dispensed Zeposia® (0,23mg+0,46mg en 0,92mg) to the patient. The health insurer will not reimburse the cost of this prescription in full. The manufacturer of…
General information
The pharmacist has dispensed Signifor® 20 mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this medicine has…
PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS
General information
The pharmacist has dispensed Isturisa® 1 mg, 5 mg or 10 mg to the patient. The health insurer will not…
PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS
General information
The pharmacist has dispensed Adhesa® 5 mg to the patient. The health insurer will not reimburse the cost of…
Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease
From February 1, 2024, the use of Jardiance® (empagliflozin) in adult patients with chronic kidney disease, with and without…
Reimbursement Scheme Kesimpta®
The health insurer does not fully reimburse Kesimpta® 20mg solution for injection in pre-filled pen. The producer of this medicine has therefore asked TBR…
Update Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg
TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg will be…
